Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...